Informace o publikaci

Growth Phase Matters: Boosting immunity via Lacticasebacillus-derived membrane vesicles and their interactions with TLR2 pathways

Logo poskytovatele
Logo poskytovatele
Autoři

SANDANUSOVÁ Miriam TURKOVA Kristyna PECHÁČKOVÁ Eva KOTOUCEK Jan ROUDNICKÝ Pavel ŠINDELÁŘ Martin KUBALA Lukáš AMBROZOVA Gabriela

Rok publikování 2024
Druh Článek v odborném periodiku
Časopis / Zdroj Journal of Extracellular Biology
Fakulta / Pracoviště MU

Přírodovědecká fakulta

Citace
www https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jex2.169
Doi http://dx.doi.org/10.1002/jex2.169
Klíčová slova growth curve; immunomodulation; Lacticaseibacillus rhamnosus; lipoteichoic acid; membrane vesicles; nanocarriers; TLR2
Přiložené soubory
Popis Lipid bi-layered particles known as membrane vesicles (MVs), produced by Gram-positive bacteria are a communication tool throughout the entire bacterial growth. However, the MVs characteristics may vary across all stages of maternal culture growth, leading to inconsistencies in MVs research. This, in turn, hinders their employment as nanocarriers, vaccines and other medical applications. In this study, we aimed to comprehensively characterize MVs derived from Lacticaseibacillus rhamnosus CCM7091 isolated at different growth stages: early exponential (6 h, MV6), late exponential (12 h, MV12) and late stationary phase (48 h, MV48). We observed significant differences in protein content between MV6 and MV48 (data are available via ProteomeXchange with identifier PXD041580), likely contributing to their different immunomodulatory capacities. In vitro analysis demonstrated that MV48 uptake rate by epithelial Caco-2 cells is significantly higher and they stimulate an immune response in murine macrophages RAW 264.7 (elevated production of TNF?, IL-6, IL-10, NO). This correlated with increased expression of lipoteichoic acid (LTA) and enhanced TLR2 signalling in MV48, suggesting that LTA contributes to the immunomodulation. In conclusion, we showed that Lacticaseibacillus rhamnosus CCM7091-derived MVs from the late stationary phase boost the immune response the most effectively, which pre-destines them for therapeutical application as nanocarriers.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info